A detailed history of Deep Track Capital, LP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Deep Track Capital, LP holds 4,950,000 shares of NTLA stock, worth $70.8 Million. This represents 3.75% of its overall portfolio holdings.

Number of Shares
4,950,000
Previous 4,800,000 3.13%
Holding current value
$70.8 Million
Previous $107 Million 5.31%
% of portfolio
3.75%
Previous 3.53%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $2.96 Million - $4.1 Million
150,000 Added 3.13%
4,950,000 $102 Million
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $11.8 Million - $16 Million
589,216 Added 13.99%
4,800,000 $107 Million
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $46.7 Million - $64.3 Million
1,960,784 Added 87.15%
4,210,784 $116 Million
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $5.79 Million - $8.09 Million
250,000 Added 12.5%
2,250,000 $68.6 Million
Q3 2023

Nov 14, 2023

BUY
$31.62 - $45.78 $36.8 Million - $53.3 Million
1,164,554 Added 139.39%
2,000,000 $63.2 Million
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $4.53 Million - $6.03 Million
130,913 Added 18.58%
835,446 $34.1 Million
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $150,948 - $203,169
4,533 Added 0.65%
704,533 $26.3 Million
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $13.3 Million - $25.1 Million
400,000 Added 133.33%
700,000 $24.4 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $16.2 Million - $21.5 Million
300,000 New
300,000 $16.8 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Deep Track Capital, LP Portfolio

Follow Deep Track Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deep Track Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Deep Track Capital, LP with notifications on news.